The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; none of the 49 sources its claims cite is checked for support yet.
CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD
Open accessAbstract
BACKGROUND: Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment in the developed world. The two forms of advanced AMD, geographic atrophy and neovascular AMD, represent different pathological processes in the macula that lead to loss of central vision. Soft drusen, characterized by deposits in the macula without visual loss, are considered to be a precursor of advanced AMD. Recently, it has been proposed that a common missense variant, Y402H, in the Complement Factor H (CFH) gene increases the risk for advanced AMD. However, its impact on soft drusen, GA, or neovascular AMD--or the relationship between them--is unclear. METHODS AND FINDINGS: We genotyped 581 Icelandic patients with advanced AMD (278 neovascular AMD, 203 GA, and 100 with mixed neovascular AMD/GA), and 435 with early AMD (of whom 220 had soft drusen). A second cohort of 431 US patients from Utah, 322 with advanced AMD (244 neovascular AMD and 78 GA) and 109 early-AMD cases with soft drusen, were analyzed. We confirmed that the CFH Y402H variant shows significant association to advanced AMD, with odds ratio of 2.39 in Icelandic patients (p = 5.9 x 10(-12)) and odds ratio of 2.14 in US patients from Utah (p = 2.0 x 10(-9)) with advanced AMD. Furthermore, we show that the Y402H variant confers similar risk of soft drusen and both forms of advanced AMD (GA or neovascular AMD). CONCLUSION: Soft drusen occur prior to progression to advanced AMD and represent a histological feature shared by neovascular AMD and GA. Our results suggest that CFH is a major risk factor of soft drusen, and additional genetic factors and/or environmental factors may be required for progression to advanced AMD.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
The CFH Y402H variant is associated with advanced AMD in Icelandic and Utah cohorts, and it confers similar risk for soft drusen and both advanced subtypes (geographic atrophy and neovascular AMD). The authors conclude CFH mainly increases risk of soft drusen, with additional genetic and/or environmental factors needed for progression to advanced AMD.
Key findings
- Advanced AMD association was confirmed: Icelandic OR 2.39 (p = 5.9 × 10−12) and Utah OR 2.14 (p = 2.0 × 10−9) in the abstract; subtype ORs were neovascular 2.32, GA 2.27, and mixed GA/neovascular 2.92 in Iceland, and neovascular 2.17 and GA 2.05 in Utah.
- Y402H conferred similar risk of soft drusen and advanced AMD: soft drusen OR 2.52 in Iceland and 2.10 in Utah; no significant association with pigmentary changes; hard drusen showed significant association in Iceland (p = 0.01, OR 1.57) but not Utah, and soft versus hard drusen differed in Iceland (p = 0.011).
- HapMap allele frequencies for CFH Y402H were 39% in Caucasians, 30.7% in Africans, 8.1% in Japanese, and 6.8% in Chinese.
Methods
- Genotyped Icelandic cohort: 581 advanced AMD patients (278 neovascular, 203 GA, 100 mixed) and 435 early AMD patients (220 with soft drusen), compared with 891 population controls or 171 longevous controls; Utah cohort: 322 advanced AMD patients (244 neovascular, 78 GA) and 109 early AMD patients with soft drusen, compared with 203 age-matched controls.
- TaqMan assay for the Icelandic cohort and direct DNA sequencing for the Utah cohort; single-marker association for rs1061170 used Fisher’s exact test (one-sided p for the at-risk allele), with variance adjustment for familial relatedness; ORs and population-attributable risk were calculated under a multiplicative model.
Limitations
- The paper does not present a formal limitations section; it notes that additional genetic and/or environmental factors may be required for progression from soft drusen to advanced AMD, and that other genes remain to be found.
- The discussion states that genotype–phenotype correlation studies are needed in non-Caucasian populations, and the analyzed cohorts were Icelandic and Utah Caucasian populations, limiting generalization.
- Evident from the text: the design is cross-sectional genotype–phenotype association, so it cannot directly establish progression or causality from soft drusen to advanced AMD; the paper also notes the Icelandic GA/neovascular ratio is an open question possibly due to genetic or environmental factors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
19 Not checked yet · 14 Own result · 11 Own interpretation
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We confirmed that the CFH Y402H variant shows significant association to advanced AMD, with odds ratio of 2.39 in Icelandic patients (p = 5.9 × 10−12)”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Abstract > Methods and Findings
boostedcorrelationaln = 581 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show that the Y402H variant confers similar risk of soft drusen and both forms of advanced AMD (GA or neovascular AMD).”
- Also stated in: § Discussion · plain
“The effect of the CFH Y402H allele on soft drusen in early AMD is similar to its effect on the advanced forms of AMD, neovascular AMD, and GA.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Abstract > Methods and Findings
boostedcorrelationaln = 581 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significant difference in CFH Y402H allele frequencies was observed when patients with soft drusen were compared with an unrelated set of patients with hard drusen (p = 0.011).”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In agreement with previous reports [3–19], the Y402H allele confers an OR of 2.32 when comparing Icelandic patients with neovascular AMD to healthy controls.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and odds ratio of 2.14 in US patients from Utah (p = 2.0 × 10−9) with advanced AMD”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Abstract > Methods and Findings
plaincorrelationaln = 431 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Y402H variant also contributes to GA, with OR of 2.27.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the variant does not show significant association to pigmentary changes found in early AMD.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient group with mixed GA/neovascular AMD gave similar results with OR of 2.92.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, there may be other genes that influence the appearance of hard drusen and pigmentary changes.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, it appears that the Y402H variant in CFH contributes to the increased risk of advanced AMD largely or entirely through its impact on the development of soft drusen as a precursor of advanced AMD.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Soft drusen are usually precursors of both forms of advanced AMD.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the Y402H variant contributes to soft drusen in early AMD, with similar ORs in the Icelandic and Utah study groups of 2.52 and 2.10, respectively (see Tables 1 and 2).”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on the comparison with population controls, the relative risk of the mutation is estimated to be 1.99 with a corresponding estimated population-attributable risk of 0.48.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: The multiplicative model holds for interpreting the odds ratio as relative risk and for calculating population-attributable risk.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The allele frequencies for CFH Y402H in Caucasians and Africans were similar, 39% versus 30.7%, while they were much lower in Asians—8.1% in the Japanese and 6.8% in the Chinese.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This CFH variant also confers increased risk although this is not significant when comparing hard drusen to controls in the Utah cohort (see Table 2).”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In Iceland we observed significant association (p = 0.01) to hard drusen but with a lower OR (1.57) (Table 1).”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The comparable association to neovascular AMD and GA was replicated in the Utah cohort, giving ORs of 2.17 and 2.05, respectively (Table 2).”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example in the Beaver Dam eye study, only 14% of the patients with soft drusen developed AMD over a 10-y period [30].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [30] Klein, 2002, Ophthalmology source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, the prevalence discrepancy between the early and advanced AMD in African Americans is consistent with our hypothesis that CFH Y402H causes soft-drusen formation, but it is not sufficient for progression to advanced AMD.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The allele frequency of Y402H is less (0.31 versus 0.39) in African Americans than in Caucasians.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We have shown that the CFH Y402H allele confers significant risk to neovascular AMD, GA, and soft drusen in early AMD in US and European Caucasian populations.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, in persons of African origin living in United States and Barbados, prevalence of early AMD and soft drusen is slightly lower than in whites, but advanced AMD is rare [34,35].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, we show that the CFH variant is a risk factor for soft drusen, but not for hard drusen or pigmentary changes, per se.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“CFH protein has been detected in choriocapillaris and within soft drusen [3].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Introduction
What the sources say
- Not checked yetcites [3] Hageman, 2005, Proc Natl Acad Sci U S A source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This observation may not be surprising given that soft drusen is comprised, in part, of complement proteins including CFH and its binding partner, complement 3b [20].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [20] Giannakis, 2003, Eur J Immunol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Biochemical analysis of drusen have indeed resulted in identification of complement components and inflammatory modulators [2–8].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Introduction
What the sources say
- Not checked yetcites [2] Hageman, 2001, Prog Retin Eye Res source
- Not checked yetcites [3] Hageman, 2005, Proc Natl Acad Sci U S A source
- Not checked yetcites [4] Mullins, 2000, Faseb J source
- Not checked yetcites [5] Mullins, 2001, Eye source
- Not checked yetcites [6] Anderson, 2002, Am J Ophthalmol source
- Not checked yetcites [7] Johnson, 2001, Exp Eye Res source
- Not checked yetcites [8] Crabb, 2002, Proc Natl Acad Sci U S A source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Several genome-wide linkage scans for AMD including ours (unpublished data) have found suggestive linkage on chromosome 1q [9–15].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Introduction
What the sources say
- Not checked yetcites [9] Klein, 1998, Arch Ophthalmol source
- Not checked yetcites [10] Weeks, 2001, Am J Ophthalmol source
- Not checked yetcites [11] Majewski, 2003, Am J Hum Genet source
- Not checked yetcites [12] Seddon, 2003, Am J Hum Genet source
- Not checked yetcites [13] Schmidt, 2004, BMC Genet source
- Not checked yetcites [14] Abecasis, 2004, Am J Hum Genet source
- Not checked yetcites [15] Iyengar, 2004, Am J Hum Genet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The Y402H allele was present in at least 60% of AMD patients with risk ratios of between 2.0 and 3.5 for one risk allele, and with risk ratios of between 3.3 and 7.4 for carriers of two risk alleles.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Introduction
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Numerous epidemiological studies have shown that the prevalence of soft drusen is two to three times greater than that of advanced AMD [33].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [33] Klein, 2004, Am J Ophthalmol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“As the patient cohort was recruited as families for a linkage analysis, we also repeated the test for association, correcting for the relatedness of the patients by extending a variance-adjustment procedure described previously [24] for sib-ships to apply to general familial relationships.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Methods > Data Analysis
What the sources say
- Not checked yetcites [24] Risch, 1998, Genome Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The 5-y incidence of soft drusen in the Reykjavik Eye Study, a population-based epidemiological study of individuals aged 50 y and older [28,29], was found to be similar to that of the Beaver Dam Eye Study in the US [30], and the Blue Mountains Eye Study in Australia [31].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Consumption of fresh fish and fishliver oil with omega-3 polyunsaturated fatty acids among Icelanders is among the highest in the world [28].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [28] Jonasson, 2003, Arch Ophthalmol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In the Icelandic population under consideration here, however, GA was found to outnumber neovascular AMD by three to one, as reported in the Reykjavik Eye Study [28,29].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Neovascular AMD outnumbers GA by approximately three to one in both the Beaver Dam Eye Study and the Blue Mountains Eye Study.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Grading was carried out using a standard grid classification suggested by the International Age-Related Maculopathy Epidemiological Study Group for age-related maculopathy and AMD [23].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Methods > Patients
What the sources say
- Not checked yetcites [23] Bird, 1995, Surv Ophthalmol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Interestingly, Seddon et al. [32] reported a trend for decreasing odds of neovascular AMD with increasing amounts of omega-3 and fresh-fish intake.”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [32] Seddon, 2001, Arch Ophthalmol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Significant genetic influence in early AMD has been demonstrated in a classical twin study comparing concordance of 226 monozygotic and 280 dizygotic twin pairs, with soft drusen and multiple hard drusen showing strong genetic influences with heritability of 57% and 81%, respectively [36].”
§ CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD > Discussion
What the sources say
- Not checked yetcites [36] Hammond, 2002, Ophthalmology source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Soft drusen are usually precursors of both forms of advanced AMD.
“Soft drusen located between the RPE and Bruch's membrane are usually precursors of both forms of advanced AMD.”
The authors state this as an assumption.
The multiplicative model holds for interpreting the odds ratio as relative risk and for calculating population-attributable risk.
“In the case of population controls and assuming the multiplicative model, in which the risks of the two alleles of the single-nucleotide polymorphism a person carries multiply [25,26], this corresponds to an estimate of the relative risk of the mutation compared to the wild-type.”
“On the basis of the frequency of the at-risk allele and the relative risk, we calculate the population-attributable risk or the reduction in the number of disease cases if the at-risk allele was removed from the population, again assuming the multiplicative model.”
The authors state this as an assumption.
Confidence intervals of relative risks and odds ratios are log-normally distributed.
“Confidence intervals of relative risks and ORs were based on the variance-adjusted tests for association, assuming a log-normal distribution.”
The paper relies on this without support.
The allele frequency of Y402H is less (0.31 versus 0.39) in African Americans than in Caucasians.
“The allele frequency of the Y402H is less (0.31 versus 0.39) in African Americans than in Caucasians.”
The paper relies on this without support.
Soft drusen and pigmentary abnormalities of the RPE are considered to be an early indication of risk of developing advanced AMD.
“Soft drusen and pigmentary abnormalities of the RPE are considered to be an early indication of risk of developing advanced AMD.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, several studies have found an association between advanced age-related macular degeneration and complement factor H, an integral component of the alternative pathway of complement activation.54–65”
From Age-related macular degeneration (2008) · cites this paper as [63]
Citations
Cites
The International HapMap Project
†The International HapMap Consortium, Genotyping centres: Baylor College of Medicine and ParAllele BioScience, Gibbs, R. A., Belmont, J. W., Hardenbol, P., Willis, T. D., Yu, F., Chinese HapMap Consortium, Yang, H., Ch'ang, L.-Y., et al. (2003) · Nature · doi:10.1038/nature02168 · Cited by 6,057
Self-citationComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208
The Five-year Incidence and Progression of Age-related Maculopathy
Klein, R., Klein, R., Jensen, S. C., & Meuer, S. M. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30368-6 · Cited by 1,154
A role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Cited by
Sorted by citations
Items 101–200 of 228
Susceptibility Genes and Progression in Age-Related Maculopathy: A Study of Single Eyes
Farwick, A., Wellmann, J., Stoll, M., Pauleikhoff, D., & Hense, H. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3953 · Cited by 34
Two genetic pathways for age-related macular degeneration
DeWan, A. T., Bracken, M. B., & Hoh, J. J. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.04.004 · Cited by 33
Droz, I., Mantel, I., Ambresin, A., Faouzi, M., Schorderet, D. F., & Munier, F. L. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.127811 · Cited by 35
Mooijaart, S. P., Koeijvoets, K. C. M. C., Sijbrands, E. J. G., Daha, M. R., & Westendorp, R. G. J. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.08.001 · Cited by 32
Maugeri, A., Barchitta, M., & Agodi, A. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13849 · Cited by 32
Modeling complex age-related eye disease
Becker, S., L'Ecuyer, Z., Jones, B. W., Zouache, M. A., McDonnell, F. S., & Vinberg, F. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101247 · Cited by 34
Brandli, A. A., Vessey, K. A., & Fletcher, E. L. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03055-1 · Cited by 33
Update on the role of genetics in the onset of age-related macular degeneration
Francis, P. J. (2011) · Clinical ophthalmology · doi:10.2147/opth.s11627 · Cited by 32
Lommatzsch, A. P., Hermans, P., Weber, B. H. F., & Pauleikhoff, D. (2007) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0649-7 · Cited by 31
Li, Y., Li, X., Li, X., Zeng, Z., Strang, N. C., Shu, X., & Tan, Z. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114531 · Cited by 30
Genetic Insights into Age-Related Macular Degeneration
Bhumika, Bora, N. S., & Bora, P. S. (2024) · Biomedicines · doi:10.3390/biomedicines12071479 · Cited by 29
Nonyane, B. A. S., Nitsch, D., Whittaker, J. C., Sofat, R., Smeeth, L. L., Chakravarthy, U., & FLETCHER, A. E. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4228 · Cited by 28
Lechanteur, Y. T. E., van de Camp, P., Smailhodzic, D., van de Ven, J. P. H., Buitendijk, G. H. S., Klaver, C. C. W., Groenewoud, J. M. M., den Hollander, A. I., Hoyng, C. B., & Klevering, B. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.18 · Cited by 28
Tamura, H., Tsujikawa, A., Yamashiro, K., Akagi-Kurashige, Y., Nakata, I., Nakanishi, H., Hayashi, H., Ooto, S., Otani, A., & Yoshimura, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.042 · Cited by 27
Kondo, N., Honda, S., Kuno, S., & Negi, A. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.004 · Cited by 25
Genetic Isolates in Ophthalmic Diseases
Sherwin, J. C., Hewitt, A. W., Ruddle, J. B., & Mackey, D. A. (2008) · Ophthalmic Genetics · doi:10.1080/13816810802334341 · Cited by 25
Seitsonen, S., Järvelä, I. E., Meri, S., Tommila, P. V., Ranta, P., & Immonen, I. J. R. (2007) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01050.x · Cited by 25
Cheung, N. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.9.1241 · Cited by 25
Dietzel, M., Pauleikhoff, D., Arning, A., Heimes, B., Lommatzsch, A. P., Stoll, M., & Hense, H. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2690-7 · Cited by 24
Nakanishi, H., Gotoh, N., Yamada, R., Yamashiro, K., Otani, A., Hayashi, H., Tsujikawa, A., Shimada, N., Ohno‐Matsui, K., Mochizuki, M., et al. (2009) · Eye · doi:10.1038/eye.2009.215 · Cited by 24
Saade, C., Ganti, B., Marmor, M. F., Freund, K. B., & Smith, R. T. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305005 · Cited by 23
Kingsmore, S. F., Lindquist, I. E., Mudge, J., & Beavis, W. D. (2007) · Biomarker Insights · doi:10.1177/117727190700200019 · Cited by 23
Losonczy, G., Fekete, Á., Vokó, Z., Takács, L., Káldi, I., Ajzner, É., Kasza, M., Vajas, A., Berta, A., & Balogh, I. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01687.x · Cited by 22
What Does Genetics Tell Us About Age-Related Macular Degeneration?
Graßmann, F., Ach, T., Brandl, C., Heid, I. M., & Weber, B. H. F. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035609 · Cited by 21
Bravo, H. C., Lee, K. E., Klein, R., Klein, R., Iyengar, S. K., & Wahba, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902906106 · Cited by 21
Epidemiology of Age-related Macular Degeneration
Seddon, J. M., & Sobrin, L. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50041-2 · Cited by 22
Soysal, Y. D., İnan, Ü. U., Küsbeci, T., & İmirzalıoğlu, N. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1214 · Cited by 19
Haas, P., Steindl, K., Schmid‐Kubista, K. E., Aggermann, T., Krugluger, W., Hageman, G. S., & Binder, S. (2009) · Eye · doi:10.1038/eye.2008.422 · Cited by 19
Teixeira, A., Silva, A. S., Lin, F. L. H., Velletri, R., Bavia, L., Belfort, R., & Isaac, L. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.01932.x · Cited by 19
Genetic Insights Into the Pathobiology of Age-related Macular Degeneration
Mullins, R. F. (2006) · International Ophthalmology Clinics · doi:10.1097/iio.0b013e31802bd3e6 · Cited by 19
Complement factor H and related proteins in age-related macular degeneration
Calippe, B., Guillonneau, X., & Sennlaub, F. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.12.003 · Cited by 18
García, M., Álvarez, L., Nogacka, A. M., González‐Iglesias, H., Escribano, J., Fernández‐Vega, B., Fernández‐Vega, Á., Fernández-Vega, L., & Coca‐Prados, M. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12790 · Cited by 18
Dong, L., Qu, Y., Jiang, H., Dai, H., Zhou, F., Xu, X., Bi, H., Pan, X., & Dang, G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.11.048 · Cited by 18
Sng, C. C. A., Cackett, P., Yeo, I. Y. S., Thalamuthu, A., Venkatraman, A., Venkataraman, D., Koh, A. H. C., Tai, E. S., Wong, T. Y., Aung, T., et al. (2010) · Ophthalmic Research · doi:10.1159/000321387 · Cited by 18
Ziskind, A., Bardien, S., van der Merwe, L., & Webster, A. R. (2008) · Ophthalmic Genetics · doi:10.1080/13816810802216472 · Cited by 17
Bonyadi, M. H. J., Yaseri, M., Bonyadi, M., Soheilian, M., & Karimi, S. (2016) · Current Eye Research · doi:10.3109/02713683.2016.1158274 · Cited by 17
Mansoor, N., Wahid, F., Azam, M., Shah, K., den Hollander, A. I., Qamar, R., & Ayub, H. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190828150625 · Cited by 17
Babanejad, M., Moein, H.-R., Akbari, M. R., Badiei, A., Yaseri, M., Soheilian, M., & Najmabadi, H. (2015) · Ophthalmic Genetics · doi:10.3109/13816810.2014.955585 · Cited by 16
Pulido, J. S., Peterson, L. M., Mutapčić, L., Bryant, S. C., & Highsmith, W. E. (2007) · Ophthalmic Genetics · doi:10.1080/13816810701649617 · Cited by 16
Hughes, A. E., Bridgett, S., Meng, W., Li, M., Curcio, C. A., Stambolian, D., & Bradley, D. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18744 · Cited by 16
Yamashiro, K., Hosoda, Y., Miyake, M., Takahashi, A., Ooto, S., & Tsujikawa, A. (2020) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00773-w · Cited by 15
Ulańczyk, Z., Grabowicz, A., Mozolewska‐Piotrowska, K., Safranow, K., Kawa, M. P., Pałucha, A., Krawczyk, M., Sikora, P., Matczyńska, E., Machaliński, B., et al. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14721 · Cited by 15
Zhang, Z., Yu, D., Yuan, J., Guo, Y., Wang, H., & Zhang, X. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.11.004 · Cited by 15
Trivizki, O., Moult, E. M., Wang, L., Iyer, P. G., Shi, Y., Gregori, G., Feuer, W. J., Fujimoto, J. G., & Rosenfeld, P. J. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.1.20 · Cited by 14
Serum VEGF and CFH in Exudative Age-Related Macular Degeneration
Haas, P., Steindl, K., Aggermann, T., Schmid‐Kubista, K. E., Krugluger, W., Hageman, G. S., & Binder, S. (2010) · Current Eye Research · doi:10.3109/02713683.2010.533808 · Cited by 14
Cure or cause: opposing roles for zinc in age-related macular degeneration
Lengyel, I., & Pető, T. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.1.1 · Cited by 13
The effect of cataract on sleep time and quality in late adulthood
Kim, Y. H., Jung, K. I., & Song, C. H. (2012) · Aging Clinical and Experimental Research · doi:10.1007/bf03654831 · Cited by 12
COMPLEMENT FACTOR H POLYMORPHISM IN AGE-RELATED MACULOPATHY IN THE CHINESE POPULATION
Gao, Y., LI, Y., Xu, L., LI, Y., Zhang, H., Jonas, J. B., & Sun, B. (2010) · Retina · doi:10.1097/iae.0b013e3181c2e086 · Cited by 12
Genetics of Age-Related Macular Degeneration: Update
Scholl, H. P. N., Fleckenstein, M., Issa, P. C., Keilhauer, C. N., Holz, F. G., & Weber, B. H. F. (2007) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-540-33672-3_3 · Cited by 14
Tumor necrosis factor gene polymorphisms in advanced non-exudative age-related macular degeneration
Bonyadi, M. H. J., Bonyadi, M. J., Ahmadieh, H., Fotuhi, N., Shoeibi, N., Saadat, S., & Yagubi, Z. (2015) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.163781 · Cited by 12
The eye--a window on the kidney
D’souza, Y. B., & Short, C. D. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp406 · Cited by 12
Yücel, D., Yılmaz, M., Durukan, A. H., & Özgül, R. K. (2012) · Ophthalmic Genetics · doi:10.3109/13816810.2012.660225 · Cited by 11
Age-related Macular Degeneration in Very Old Individuals with Family History
Geirsdóttir, Á., Stefánsson, E., Jónasson, F., Helgadóttir, G., & Sigurðsson, H. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.057 · Cited by 11
Kim, Y. H., Kim, H., Mok, J. W., & Joo, C. (2013) · Ophthalmic Genetics · doi:10.3109/13816810.2012.749287 · Cited by 11
Application of Nutrigenomics in Eye Health
Delcourt, C. (2007) · Forum of nutrition/Bibliotheca Nutritio et dieta · doi:10.1159/000107176 · Cited by 10
New Technologies to Study Functional Genomics of Age-Related Macular Degeneration
Nguyen, T., Urrutia-Cabrera, D., Liou, R. H.-C., Luu, C. D., Guymer, R. H., & Wong, R. C. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.604220 · Cited by 9
Okur, V., ÇETİN, O., Çetin, E. N., Tepeli, E., Bulğu, Y., & Yıldırım, C. (2014) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12376 · Cited by 9
Ho, L., van Leeuwen, R., de Jong, P. T. V. M., Vingerling, J. R., & Klaver, C. C. W. (2012) · Springer eBooks · doi:10.1007/978-3-642-22107-1_1 · Cited by 9
Chong, E. W. T., Islam, A. F. M., Robman, L. D., Aung, K. Z., Richardson, A. J., Baird, P. N., & Guymer, R. H. (2015) · Retina · doi:10.1097/iae.0000000000000417 · Cited by 8
GENOTYPE–PHENOTYPE ASSOCIATIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Hogg, R. E., McKay, G. J., Hughes, A. E., Muldrew, K. A., & Chakravarthy, U. (2012) · Retina · doi:10.1097/iae.0b013e31824dadf1 · Cited by 8
Playing ‘hide-and-seek’ with factor H: game-theoretical analysis of a single nucleotide polymorphism
Hummert, S., Glock, C., Lang, S. N., Hummert, C., Skerka, C., Zipfel, P. F., Germerodt, S., & Schuster, S. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0963 · Cited by 8
Genetics of Age-Related Macular Degeneration
Kasuga, D. T., Chen, Y., & Zhang, K. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0125-4_1 · Cited by 7
Self-citationHao, X., Xie, L., Tang, Y.-Z., Xie, W., Zhang, Z., Qi, Y.-X., Xiao, W.-Z., & Zhang, J. (2015) · PubMed Central · Cited by 7
Arslan, J., & Baird, P. N. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0183 · Cited by 7
10q26 Is Associated with Increased Risk of Age-Related Macular Degeneration in the Utah Population
Cameron, D. J., Yang, Z., Tong, Z., Zhao, Y., Praggastis, A., Brinton, E., Harmon, J. N., Chen, Y., Pearson, E., Bernstein, P. S., et al. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_29 · Cited by 7
Self-citationDry age-related macular degeneration and age-related macular degeneration pathogenesis
Zarbin, M. A., & Sunness, J. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-2983-7.00068-1 · Cited by 6
Conley, Y. P., Jakobsdóttir, J., Mah, T. S., Weeks, D. E., Klein, R. B., Kuller, L. H., Ferrell, R. E., & Gorin, M. B. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.012 · Cited by 6
Chen, J., Yang, Y., Zheng, Y., Qiu, M., Xie, M., Lin, W., Zhang, M., Pang, C. P., & Chen, H. (2013) · Europe PMC (PubMed Central) · Cited by 6
Sodi, A., Passerini, I., Bacherini, D., Boni, L., Palchetti, S., Murro, V., Caporossi, O., Mucciolo, D. P., Franco, F. G. S., Vannozzi, L., et al. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1525753 · Cited by 6
Regenerative medicine as a novel strategy for AMD treatment: a review
Tavakoli, Z., Yazdian, F., Tabandeh, F., & Sheikhpour, M. (2019) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ab269a · Cited by 6
Novel sequence elements define ancestral haplotypes of the region encompassing complement factor H
Williamson, J. F., McLure, C. A., Baird, P. N., Male, D. A., Millman, J. A., Lawley, B., Ashdown, M. L., Keating, P. J., & Dawkins, R. L. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.01.016 · Cited by 6
Toward Personalized Medicine for Age-Related Macular Degeneration
Souied, E. H., & Leveziel, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.05.022 · Cited by 6
Dunaief, D. M., Cwanger, A., & Dunaief, J. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-401717-7.00063-0 · Cited by 5
Azuma, M., Chung, K. D., Fujii, A., & Shearer, T. R. (2010) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2010.0042 · Cited by 5
Age-related macular degeneration (AMD): Current concepts in pathogenesis and prospects for treatment
Shin, O. R., & Kim, Y. H. (2013) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-012-0374-0 · Cited by 5
Karkhane, R., Ahmadraji, A., Esfahani, M. R., Roohipourmoallai, R., Harandi, Z. A., Lashay, A., Kermani, M. S., Roozafzoon, R., & Khoshzaban, A. (2016) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2016.01.003 · Cited by 5
Pathobiology of the Outer Retina: Genetic and Nongenetic Causes of Disease
Haider, N. B., Cruz, N. M., Allocca, M., & Yuan, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04706-7 · Cited by 6
de CODE and Iceland: A Critique
Árnason, E., & D, B. A. M. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0005180.pub2 · Cited by 6
Cruz-González, F., Lorenzo-Pérez, R., Cañete-Campos, C., Hernández-Galilea, E., & González‐Sarmiento, R. (2012) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2012.04.019 · Cited by 4
Genetik und Risikofaktoren der exsudativen AMD
Dietzel, M., Farwick, A., & Hense, H. (2010) · Der Ophthalmologe · doi:10.1007/s00347-010-2141-8 · Cited by 4
Soheilian, R., Bonyadi, M. H. J., Moein, H.-R., Babanejad, M., Ramezani, A., Yaseri, M., & Soheilian, M. (2016) · International Ophthalmology · doi:10.1007/s10792-016-0373-6 · Cited by 4
Homocysteine in the Pathogenesis of Chronic Glaucoma
Mustafa, R. A., & Colin, I. (2011) · InTech eBooks · doi:10.5772/18506 · Cited by 4
Histopathology of Age-Related Macular Degeneration and Implications for Pathogenesis and Therapy
Chee, R.-I., Mahrous, A., Koenig, L., Mandel, L. S., Yazdanie, F., Chan, C., & Patel, M. M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_3 · Cited by 4
Is our current clinical classification of AMD up to the job?
Malek, G. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098715 · Cited by 4
Cruz-González, F., Lorenzo-Pérez, R., Cañete-Campos, C., Hernández-Galilea, E., & González‐Sarmiento, R. (2013) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2013.02.001 · Cited by 3
Huang, Y., Liao, W., Lin, H., Huang, Y.-T., Chang, Y., Liu, T., Chen, Y.-C., Weng, A. L., & Tsai, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063230 · Cited by 3
Williamson, J. F., McLure, C. A., Guymer, R. H., Baird, P. N., Millman, J. A., Cantsilieris, S., & Dawkins, R. L. (2011) · Genomics · doi:10.1016/j.ygeno.2011.08.002 · Cited by 3
Advanced nanomedicines for the treatment of age-related macular degeneration
Kwon, Y., & Han, Z. (2024) · Nanoscale · doi:10.1039/d4nr01917b · Cited by 3
Wahba, G., Ramakrishnan, R., & Bravo, H. C. (2008) · Cited by 3
Membranoproliferative Glomerulonephritis
Licht, C. P. B., & Mengel, M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04883-5.50023-4 · Cited by 3
Review of Emerging Treatments for Age-Related Macular Degeneration
Zarbin, M. A., & Rosenfeld, P. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-606-7_1 · Cited by 3
The Role of Inflammation in Age-Related Macular Degeneration
Harris, J. M., & Wu, D. M. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000578 · Cited by 2
CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy
Zhang, Y., Zou, H., Ni, X., Tie, F., Xu, B., Kang, Y., Xiang, W., Li, Y., Jia, C., Tan, Y. C. R. S., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000983 · Cited by 2
Age Related Macular Degeneration: a Complex Pathology
Kumar, S., Fu, Y., & Moran, J. A. (2014) · Cited by 2
Gene therapy in age-related macular degeneration
Maurya, R. P., & Gupta, S. V. (2023) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.2023.001 · Cited by 2
Francis, P. J. (2010) · Wiley eBooks · doi:10.1002/9780470015902.a0023109 · Cited by 2
Encoding dissimilarity data for statistical model building
Wahba, G. (2010) · Journal of Statistical Planning and Inference · doi:10.1016/j.jspi.2010.04.025 · Cited by 1
Ho, L., van Leeuwen, R., de Jong, P. T. V. M., Vingerling, J. R., & Klaver, C. C. W. (2011) · Springer eBooks · doi:10.1007/978-3-642-20870-6_1 · Cited by 1
Textbook of Vitreoretinal Diseases and Surgery
Natarajan, S., Hussain, N., & Dabir, S. (2009) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10962 · Cited by 1
Toward a Higher Fidelity Model of AMD
Raisler, B. J., Nozaki, M., Baffi, J., Hauswirth, W. W., & Ambati, J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_21 · Cited by 1
Metadata
- Authors
- Magnusson, K. P., Duan, S., Sigurdsson, H., Petursson, H., Yang, Z., Zhao, Y., Bernstein, P. S., Ge, J., Jonasson, F., Stefansson, E., Helgadottir, G., Zabriskie, N. A., Jonsson, T., Björnsson, A., Thorlacius, T., Jonsson, P. V., Thorleifsson, G., Kong, A., Stefansson, H., Zhang, K., Stefansson, K., & Gulcher, J. R.
- Affiliations
- University of Utah (US)
- Zhongshan Ophthalmic Center, Sun Yat-sen University (CN)
- deCODE Genetics (Iceland) (IS)
- Corresponding author
- Zhang, Kang
- Gulcher, Jeffrey R
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2005-11-29
- Volume
- 3
- Issue
- 1
- Pages
- e5
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC1288033
- OpenAlex
- W2091742941
- Semantic Scholar
- 0e0225f27a97fcd2fe1c5661164e1192004ff2df
- Cited by
- 226
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 3 · 2016: 7 · 2015: 9 · 2014: 10 · 2013: 9 · 2012: 18
- FWCI
- 25.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- American Health Assistance Foundation
- Ronald McDonald House Charities
- Deutsches Krebsforschungszentrum
- National Institutes of Health (R01EY14428, M01-RR00064)
- National Eye Institute (R01EY014448, R01EY014428, R01EY14428, R01EY14448, P30EY014800)
- National Center for Research Resources (M01-RR 00064, M01RR000064)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, complement factor H, soft drusen, geographic atrophy, neovascular AMD, genetic risk factors, disease progression, early AMD
- MeSH terms
- Humans, Iceland, Macular Degeneration, Mutation, Risk Factors, Utah, Retinal Drusen, Odds Ratio, Complement Factor H, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
